A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma

This is an investigator-initiated, single-center, early-phase clinical study comprising dose escalation and dose expansion phases, designed to evaluate the safety and efficacy of IMV102 in subjects with relapsed/refractory multiple myeloma (RRMM). Eligible subjects will receive an infusion of IMV102 injection. Blood and urine samples will be collected before and after infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety assessments. Tumor response will be evaluated according to the International Myeloma Working Group (IMWG) uniform response criteria (2016). Assessments wi

Trial Details

NCT ID
NCT07493135
Phase
EARLY_PHASE1
Sponsor
Suzhou Immunofoco Biotechnology Co., Ltd
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • IMV102 treatment
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Chongqing, China|29.56026,106.55771
  • Shanghai, China|31.22222,121.45806
  • Zhengzhou, China|34.75778,113.64861

Key Eligibility Criteria

  • Age: Aged 18 to 80 years (inclusive), of either sex.
  • Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Diagnosed with relapsed/refractory multiple myeloma according to the IMWG criteria, who have received at least 3 prior lines of therapy (including …
  • Reproductive Status: Subjects of childbearing potential and their partners must agree to use medically accepted highly effective contraceptive meth…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →